M. D. Anderson receives one of its largest private research gifts

September 05, 2002

HOUSTON -- The University of Texas M. D. Anderson Cancer Center has received a $15 million gift -- one of the largest private donations in its history to fund research -- from the Commonwealth Foundation for Cancer Research and Mr. and Mrs. William H. Goodwin Jr. of Richmond, Va.

The gift will fund a molecular diagnostics and therapeutics program at M. D. Anderson, which is aimed at furthering the institution's progress in translational research. Among various initiatives, the contribution will help launch more than 10 new research projects that will enable laboratory research to be more quickly converted -- or translated -- from knowledge into direct patient care applications.

"This gift will accelerate our ability to use our understanding of the biology of cancer to develop drugs that will target specific abnormalities in particular patients' cancers. Diagnostic techniques will be developed that identify which drugs to use and whether or not they are effective," explains Dr. Robert Bast, vice president for translational research at M. D. Anderson. "We appreciate the generosity of the Goodwins and their foundation and their confidence in M. D. Anderson to make this significant investment in M. D. Anderson's efforts."

"The Goodwins' gift will help us realize our vision of translating knowledge from the lab to the clinic and of taking clinical observations back to the laboratory," says Dr. John Mendelsohn, president of M. D. Anderson. "Making new therapies available to patients as quickly as possible is our responsibility as scientists and care givers."

The Commonwealth Foundation for Cancer Research gift will support six different areas, which are driving M. D. Anderson's translational research effort. They are:"Finding effective strategies to fight cancer is the goal of all involved. We have seen firsthand the tragic consequences of cancer and want to do what we can to help find better treatments and hopefully the ultimate cure for cancer," says Alice Goodwin.

"We have tried very hard to support areas of research that we feel could be the most beneficial to those afflicted with cancer now and in the future. We have talked with many prominent doctors and researchers and feel that they are on the edge of an explosion of many possible strategies to combat and cure cancer. M. D. Anderson's efforts in translational research seem to be in line with the results we are hoping to accomplish with our support."

Bill Goodwin adds, "We were very impressed with the research efforts taking place at M. D. Anderson, particularly in the areas of translational research. We believe that Dr. Mendelsohn, Dr. Bast and his team are outstanding, and we are thankful that we are able to support M. D. Anderson's research efforts."

In addition to M. D. Anderson's research pursuits made possible by the gift, scientists will be collaborating with their counterparts at institutions which have received similar funding from the foundation, including Johns Hopkins University, Memorial Sloan-Kettering Cancer Center and Mayo Clinic.

Bill Goodwin is chairman of CCA Industries Inc., a diversified holding company headquartered in Richmond, Va. Some of their current business interests include The Jefferson Hotel, which is a 5-Star, 5-Diamond historic hotel in Richmond, The Hermitage Hotel in Nashville, Tenn., and Kiawah Island Resort, which is located near Charleston, S.C.
-end-


University of Texas M. D. Anderson Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.